All articles by GlobalData 

  1. Idiopathic pulmonary fibrosis higher than previously reported in the UK

    Idiopathic pulmonary fibrosis (IPF) is a chronic disease where scar tissues develop in the lungs. IPF causes the lungs to…
    Read More…

    26 Apr
  2. Struggling sales of antibiotics are feeding through to upcoming launches

    Flawed reimbursement dynamics are significantly hurting recent antibiotic sales, which are failing market projections, and similar repercussions are expected for…
    Read More…

    24 Apr
  3. With gaps in Parkinson’s treatment, promising pipeline drugs may address key unmet needs

    World Parkinson’s Day, on April 11, has the aim of raising global awareness and understanding of the issues faced by…
    Read More…

    23 Apr
  4. Risk of stroke is high even with moderate intake of alcohol

    A stroke is a life-threatening medical condition and the major risk factors associated with the development of stroke include hypertension,…
    Read More…

    12 Apr
  5. Diagnosed prevalent cases of multiple myeloma on the rise

    The burden of multiple myeloma (MM), a blood cancer of the white blood cells known as plasma cells, is expected…
    Read More…

    11 Apr
  6. Governments are playing a bigger role in cell and gene therapy manufacturing

    Government institutions are becoming increasingly engaged in cell and gene therapy manufacturing across the US and UK industries, according to…
    Read More…

    10 Apr
  7. Roche’s novel combination shows early signs of promise in triple-negative breast cancer

    Roche has unveiled promising Phase Ib clinical trial data evaluating the safety and efficacy of its pan-Akt inhibitor, ipatasertib, in…
    Read More…

    10 Apr
  8. Increased diagnosis and comprehensive treatment of mood disorders in cases of BED is crucial to recovery

    Binge eating disorder (BED) is characterised by eating large quantities of food all at once during a set time period….
    Read More…

    10 Apr
  9. Dupixent likely to maintain its position in the market for atopic dermatitis

    Regeneron Pharmaceuticals’ Dupixent (dupilumab) is likely to maintain its foothold in moderate-to-severe atopic dermatitis (AD) in the foreseeable future considering…
    Read More…

    9 Apr
  10. PARP inhibitors make inroads in pancreatic cancer

    Preliminary data from a Phase II trial of Clovis Oncology’s Rubraca (rucaparib) for maintenance of advanced BRCA- or PALB2-related pancreatic…
    Read More…

    9 Apr
Close
Close
Close

Go Top